Persistence of antiretroviral treatment in emtricitabine/tenofovir (FTC/TDF) users vs other NRTI in ART-na ve patients > 50 years: TRIP study

Pedrol, E.; Castano, M.; Olalla, J.; Domingo, P.; Arazo, P.; Gomez-Sirvent, J.; Riera, Melchor; Pulido, F.; Vera, F.; Vergara, A.; Aguirrebengoa, K.; Portilla, J.; Blanco, J.

doi:10.7448/IAS.15.6.18292

Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/12982

View

000320654200358.pdf (178.6Kb)

Identifiers

URI: http://hdl.handle.net/20.500.13003/12982

DOI: 10.7448/IAS.15.6.18292

eISSN: 1758-2652

WOS ID: 000320654200358

Embase PUI: L71227938

Metrics

Export

External links

Publication date

2012-11

Document type

contribution to journal

Citation

Pedrol E, Castano M, Olalla J, Domingo P, Arazo P, Gomez-Sirvent J, et al. Persistence of antiretroviral treatment in emtricitabine/tenofovir (FTC/TDF) users vs other NRTI in ART-na ve patients > 50 years: TRIP study [meeting abstract]. J Int AIDS Soc. 2012 Nov;15:171-2.

Publisher version

https://dx.doi.org/10.7448/IAS.15.6.18292

This item appears in following Docusalut collections

Hospital Universitario Son Espases - HUSE > Comunicación científica

This item's license is described as Attribution 3.0 Unported